Journal of Clinical Oncology, Vol 16, 3115-3120, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Low biologic aggressiveness in breast cancer in women using hormone replacement therapy

K Holli, J Isola and J Cuzick
Department of Oncology, University Hospital of Tampere, Institute of Medical Technology, University of Tampere, Finland. kaholli@tays.fi

PURPOSE: Hormone replacement therapy (HRT) has been associated with an increased risk for breast cancer. Cancers in women who use HRT are often less advanced, and lower mortality has been reported in those who use HRT than in nonusers. We sought to explain this by a comparison of indicators of tumor aggressiveness in patients who received HRT with those in patients who did not. PATIENTS AND METHODS: A population-based cohort of 477 postmenopausal women with breast cancer were interviewed for the use, type, and duration of HRT. Clinical variables and indicators of tumor aggressiveness (histologic grade, hormone receptors, DNA ploidy, S-phase fraction, and c-erbB-2 oncoprotein overexpression) were analyzed. RESULTS: Breast tumors from HRT users were smaller (odds ratio, 0.47; P=.005), had better histologic differentiation (P=.04), and had a lower proliferation rate (S-phase fraction, P=.009) than tumors from nonusers. These differences persisted after adjustments for age and method of diagnosis (mammography screening v self-referral) by multiple logistic regression. No significant differences were observed in the estrogen (ER) or progesterone receptor content, c-erbB-2 oncogene overexpression, or axillary node involvement. A subgroup analysis showed that the tumor proliferation rates among HRT users were significantly lower only if HRT had been used at the time of diagnosis (P=.001). The type of HRT (estrogen v combination of estrogen and progesterone) was not associated with any clinical parameter or tumor phenotype. The association of HRT with lower proliferation rate and smaller tumor size was exclusively caused by ER-positive tumors (P=.0001 and P=.0035 v P > .1, respectively). CONCLUSION: The results indicate that breast cancer in women who receive HRT is biologically less aggressive than those without previous HRT. The lower cell- proliferation rate and smaller tumor size found in ER-positive tumors from current HRT users suggest a direct ER-mediated growth inhibitory effect of HRT on established breast tumors. This may at least partly explain why breast cancer in HRT users has a more favorable clinical course.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. Sestak, F. Sapunar, and J. Cuzick Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial J. Clin. Oncol., October 20, 2009; 27(30): 4961 - 4965. [Abstract] [Full Text] [PDF]

				T. E. Slanger, J. C. Chang-Claude, N. Obi, S. Kropp, J. Berger, E. Vettorazzi, W. Braendle, G. Bastert, S. Hentschel, and D. Flesch-Janys Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1188 - 1196. [Abstract] [Full Text] [PDF]

				A. Fabre, A. Fournier, S. Mesrine, A. Gompel, J. Desreux, F. Berrino, M.-C. Boutron-Ruault, I. Romieu, and F. Clavel-Chapelon Progestagens Use Before Menopause and Breast Cancer Risk According to Histology and Hormone Receptors Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2723 - 2728. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski and R. L. Prentice Menopausal Hormone Therapy in BRCA1 Mutation Carriers: Uncertainty and Caution J Natl Cancer Inst, October 1, 2008; 100(19): 1341 - 1343. [Full Text] [PDF]

				P. A. Newcomb, K. M. Egan, A. Trentham-Dietz, L. Titus-Ernstoff, J. A. Baron, J. M. Hampton, M. J. Stampfer, and W. C. Willett Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 864 - 871. [Abstract] [Full Text] [PDF]

				A. Fournier, A. Fabre, S. Mesrine, M.-C. Boutron-Ruault, F. Berrino, and F. Clavel-Chapelon Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor-Defined Invasive Breast Cancer J. Clin. Oncol., March 10, 2008; 26(8): 1260 - 1268. [Abstract] [Full Text] [PDF]

				A. M. Brewster, K.-A. Do, P. A. Thompson, K. M. Hahn, A. A. Sahin, Y. Cao, M. M. Stewart, J. L. Murray, G. N. Hortobagyi, and M. L. Bondy Relationship Between Epidemiologic Risk Factors and Breast Cancer Recurrence J. Clin. Oncol., October 1, 2007; 25(28): 4438 - 4444. [Abstract] [Full Text] [PDF]

				A. M. Chiarelli, V. A. Kirsh, N. S. Klar, R. Shumak, R. Jong, E. Fishell, M. J. Yaffe, and N. F. Boyd Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1856 - 1862. [Abstract] [Full Text] [PDF]

				C. Antoine, F. Liebens, B. Carly, A. Pastijn, and S. Rozenberg Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial Hum. Reprod., March 1, 2004; 19(3): 741 - 756. [Abstract] [Full Text] [PDF]

				J. R. Daling, K. E. Malone, D. R. Doody, L. F. Voigt, L. Bernstein, P. A. Marchbanks, R. J. Coates, S. A. Norman, L. K. Weiss, G. Ursin, et al. Association of Regimens of Hormone Replacement Therapy to Prognostic Factors among Women Diagnosed with Breast Cancer Aged 50-64 Years Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1175 - 1181. [Abstract] [Full Text]

				S. H. Amin, C. L. Kuhle, and L. A. Fitzpatrick Comprehensive Evaluation of the Older Woman Mayo Clin. Proc., September 1, 2003; 78(9): 1157 - 1185. [Abstract] [PDF]

				R. T. Chlebowski, S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass, D. Lane, R. J. Rodabough, M. A. Gilligan, M. G. Cyr, C. A. Thomson, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial JAMA, June 25, 2003; 289(24): 3243 - 3253. [Abstract] [Full Text] [PDF]

				P. H. Gann and M. Morrow Combined Hormone Therapy and Breast Cancer: A Single-Edged Sword JAMA, June 25, 2003; 289(24): 3304 - 3306. [Full Text] [PDF]

				J. Cheek, J. Lacy, S. Toth-Fejel, K. Morris, K. Calhoun, and R. F. Pommier The Impact of Hormone Replacement Therapy on the Detection and Stage of Breast Cancer Arch Surg, September 1, 2002; 137(9): 1015 - 1021. [Abstract] [Full Text] [PDF]

				G. Ursin, C.-C. Tseng, A. Paganini-Hill, S. Enger, P. C. Wan, S. Formenti, M. C. Pike, and R. K. Ross Does Menopausal Hormone Replacement Therapy Interact With Known Factors to Increase Risk of Breast Cancer? J. Clin. Oncol., February 1, 2002; 20(3): 699 - 706. [Abstract] [Full Text] [PDF]

				J. Cuzick Is Hormone Replacement Therapy Safe for Breast Cancer Patients? J Natl Cancer Inst, May 16, 2001; 93(10): 733 - 733. [Full Text] [PDF]

				E. S. O'Meara, M. A. Rossing, J. R. Daling, J. G. Elmore, W. E. Barlow, and N. S. Weiss Hormone Replacement Therapy After a Diagnosis of Breast Cancer in Relation to Recurrence and Mortality J Natl Cancer Inst, May 16, 2001; 93(10): 754 - 761. [Abstract] [Full Text] [PDF]

				S. M. Gapstur, M. Morrow, and T. A. Sellers Hormone Replacement Therapy and Risk of Breast Cancer With a Favorable Histology: Results of the Iowa Women's Health Study JAMA, June 9, 1999; 281(22): 2091 - 2097. [Abstract] [Full Text] [PDF]

				B. Fowble, A. Hanlon, G. Freedman, A. Patchefsky, H. Kessler, N. Nicolaou, J. Hoffman, E. Sigurdson, M. Boraas, and L. Goldstein Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation J. Clin. Oncol., June 1, 1999; 17(6): 1680 - 1680. [Abstract] [Full Text] [PDF]

				M. A. Cobleigh, F. E. Norlock, D. M. Oleske, and A. Starr Hormone Replacement Therapy and High S Phase in Breast Cancer JAMA, April 28, 1999; 281(16): 1528 - 1530. [Abstract] [Full Text] [PDF]